160 related articles for article (PubMed ID: 35129305)
21. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
Alonso-Álvarez S; Magnano L; Alcoceba M; Andrade-Campos M; Espinosa-Lara N; Rodríguez G; Mercadal S; Carro I; Sancho JM; Moreno M; Salar A; García-Pallarols F; Arranz R; Cannata J; Terol MJ; Teruel AI; Rodríguez A; Jiménez-Ubieto A; González de Villambrosia S; Bello JL; López L; Monsalvo S; Novelli S; de Cabo E; Infante MS; Pardal E; García-Álvarez M; Delgado J; González M; Martín A; López-Guillermo A; Caballero MD
Br J Haematol; 2017 Sep; 178(5):699-708. PubMed ID: 28782811
[TBL] [Abstract][Full Text] [Related]
22. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.
Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA
Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097
[TBL] [Abstract][Full Text] [Related]
23. The role of "watch and wait" in intestinal follicular lymphoma in rituximab era.
Tari A; Asaoku H; Takata K; Fujimori S; Tanaka S; Fujihara M; Koga T; Yoshino T
Scand J Gastroenterol; 2016 Mar; 51(3):321-8. PubMed ID: 26382560
[TBL] [Abstract][Full Text] [Related]
24. Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.
Sarkozy C; Maurer MJ; Link BK; Ghesquieres H; Nicolas E; Thompson CA; Traverse-Glehen A; Feldman AL; Allmer C; Slager SL; Ansell SM; Habermann TM; Bachy E; Cerhan JR; Salles G
J Clin Oncol; 2019 Jan; 37(2):144-152. PubMed ID: 30481079
[TBL] [Abstract][Full Text] [Related]
25. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices.
Nooka AK; Nabhan C; Zhou X; Taylor MD; Byrtek M; Miller TP; Friedberg JW; Zelenetz AD; Link BK; Cerhan JR; Dillon H; Sinha R; Shenoy PJ; Levy D; Dawson K; Hirata JH; Flowers CR
Ann Oncol; 2013 Feb; 24(2):441-448. PubMed ID: 23041589
[TBL] [Abstract][Full Text] [Related]
26. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
[TBL] [Abstract][Full Text] [Related]
27. [Follicular lymphoma: first - line selection criteria of treatment].
Nesterova ES; Kravchenko SK; Kovrigina AM; Gemdzhian EG; Plastinina LV; Babaeva FE; Obukhova TN; Magomedova AU; Gaponova TV; Kremenetskaya AM; Vorobyev AI
Ter Arkh; 2019 Aug; 91(8):75-83. PubMed ID: 32598757
[TBL] [Abstract][Full Text] [Related]
28. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
Watanabe T; Tobinai K; Wakabayashi M; Morishima Y; Kobayashi H; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Yoshino T; Nawano S; Terauchi T; Hotta T; Nagai H; Tsukasaki K;
Lancet Haematol; 2018 Nov; 5(11):e520-e531. PubMed ID: 30389034
[TBL] [Abstract][Full Text] [Related]
29. Assessing the Effectiveness of Treatment Sequences for Older Patients With High-risk Follicular Lymphoma With a Multistate Model.
Çağlayan Ç; Terawaki H; Ayer T; Goldstein JS; Rai A; Chen Q; Flowers C
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):300-309.e5. PubMed ID: 30686772
[TBL] [Abstract][Full Text] [Related]
30. [Updates in treatment strategies for follicular lymphoma].
Fukuhara N
Rinsho Ketsueki; 2020; 61(9):1252-1258. PubMed ID: 33162523
[TBL] [Abstract][Full Text] [Related]
31. Watchful waiting is an acceptable treatment option for asymptomatic primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: A retrospective study.
Mizuhara K; Kobayashi T; Nakao M; Takahashi R; Kaneko H; Shimura K; Hirakawa K; Uoshima N; Wada K; Kawata E; Isa R; Fujino T; Tsukamoto T; Mizutani S; Shimura Y; Yoneda A; Watanabe A; Sotozono C; Kuroda J
Cancer Med; 2023 Feb; 12(3):3134-3144. PubMed ID: 36097396
[TBL] [Abstract][Full Text] [Related]
32. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.
Murakami S; Kato H; Higuchi Y; Yamamoto K; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
Ann Hematol; 2016 Aug; 95(8):1259-69. PubMed ID: 27220639
[TBL] [Abstract][Full Text] [Related]
33. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
[TBL] [Abstract][Full Text] [Related]
34. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era.
Cheah CY; Chihara D; Ahmed M; Davis RE; Nastoupil LJ; Phansalkar K; Hagemeister FB; Fayad LE; Westin JR; Oki Y; Fanale MA; Romaguera JE; Wang ML; Lee H; Turturro F; Samaniego F; Rodriguez MA; Neelapu SS; Fowler NH
Ann Oncol; 2016 May; 27(5):895-901. PubMed ID: 26802151
[TBL] [Abstract][Full Text] [Related]
35. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.
Martinelli G; Montoro J; Vanazzi A; Andreola G; Liptrott S; Radice D; Negri M; Preda L; Pruneri G; Laszlo D
Hematol Oncol; 2015 Dec; 33(4):129-35. PubMed ID: 25047267
[TBL] [Abstract][Full Text] [Related]
36. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
37. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
38. Individualized management of follicular lymphoma.
Bai B; Huang HQ
Chin Clin Oncol; 2015 Mar; 4(1):7. PubMed ID: 25841714
[TBL] [Abstract][Full Text] [Related]
39. [The current therapeutic landscape for follicular lymphoma].
Kobayashi T
Rinsho Ketsueki; 2021; 62(8):1070-1076. PubMed ID: 34497193
[TBL] [Abstract][Full Text] [Related]
40. Current approaches and future perspectives for advanced-stage follicular lymphoma with a low tumor burden.
Fukuhara N; Ishizawa K
Jpn J Clin Oncol; 2019 Apr; 49(4):306-310. PubMed ID: 30715424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
